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Validation of ultrasound 
bioimaging to predict worm burden 
and treatment efficacy in preclinical 
filariasis drug screening models
Amy E. Marriott, Hanna Sjoberg  , Hayley Tyrer, Joanne Gamble, Emma Murphy,  
John Archer, Andrew Steven, Mark J. Taylor  & Joseph D. Turner
Filariasis is a global health problem targeted for elimination. Curative drugs (macrofilaricides) are 
required to accelerate elimination. Candidate macrofilaricides require testing in preclinical models 
of filariasis. The incidence of infection failures and high intra-group variation means that large group 
sizes are required for drug testing. Further, a lack of accurate, quantitative adult biomarkers results 
in protracted timeframes or multiple groups for endpoint analyses. Here we evaluate intra-vital 
ultrasonography (USG) to identify B. malayi in the peritonea of gerbils and CB.17 SCID mice and 
assess prognostic value in determining drug efficacy. USG operators, blinded to infection status, 
could detect intra-peritoneal filarial dance sign (ipFDS) with 100% specificity and sensitivity, when 
>5 B. malayi worms were present in SCID mice. USG ipFDS was predictive of macrofilaricidal activity 
in randomized, blinded studies comparing flubendazole, albendazole and vehicle-treated SCID mice. 
Semi-quantification of ipFDS could predict worm burden >10 with 87–100% accuracy in SCID mice or 
gerbils. We estimate that pre-assessment of worm burden by USG could reduce intra-group variation, 
obviate the need for surgical implantations in gerbils, and reduce total SCID mouse use by 40%. Thus, 
implementation of USG may reduce animal use, refine endpoints and negate invasive techniques for 
assessing anti-filarial drug efficacy.
The filarial neglected tropical diseases (NTDs), lymphatic filariasis (LF) and onchocerciasis are prioritized for 
elimination by the World Health Organization by 2030, in line with The United Nations Sustainable Development 
Goals1,2. LF, caused by Wuchereria bancrofti, Brugia malayi and B. timori affects an estimated 120 million people3 
with another billion people at risk of infection4. Clinically, the disease presents as elephantiasis and hydrocele 
in approximately 40 million LF patients, and is a major cause of global disability2. Onchocerciasis is caused by 
the related filaria, Onchocerca volvulus and infects an estimated 37 million individuals, mainly in Sub-Saharan 
Africa. In its most severe presentation, ocular onchocerciasis (river blindness), which affects 0.8 million people, 
is a major cause of preventable blindness1.
Current strategies to eliminate LF and onchocerciasis are centered around The World Health Organization’s 
(WHO) Expanded Special Project for Elimination of NTDs, in which repeated doses of preventable chemo-
therapies (PCT) are administered annually to endemic populations through mass drug administration (MDA) 
campaigns5. These PCT drugs, namely ivermectin, albendazole and diethylcarbamazine (DEC), target the trans-
missible larval stage of the parasites the microfilaria (mf). Although effective PCT treatments temporarily induce 
sterilization of adult worms, they do not (in current MDA recommended regimens) mediate significant macro-
filaricidal (curative) activity. With a reproductive life-span of 5 years (LF)6 or 10 years (onchocerciasis)7. MDA has 
to be delivered with high population coverage for at least this period of time to deliver transmission break points. 
Issues of adherence to treatment, problems of sustained drug delivery and development of drug resistance have 
culminated in the lack of expected elimination outcomes in certain endemic foci8–10.
A recognized solution to this problem is the development of new drugs for filariasis which can mediate 
curative efficacy with following a short-course, test-and-treat strategy. New drug candidates (either repurposed 
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registered drugs or new chemical entities) require rigorous assessment of efficacy in preclinical models of filari-
asis. Current standard screening models use either surrogate species (the cotton rat filaria Litomosoides sigmo-
dontis and the dog filaria, B. pahangi) or a human sub-periodic strain of B. malayi. All three species of lymphatic 
filariae can establish long-term, fecund infections (≥8 months) in mongolian gerbils following inoculation with 
infectious stage larvae. L. sigmodontis adults infect the pleural cavity via migration through the lymphatics, whilst 
Brugia spp establish in either the peritoneal cavity or the lymphatics, depending on route of infection. For L. sig-
modontis, shorter term murine infections can be established (for 2–3 months) in BALB/c inbred mice. Also for 
Brugia spp., use of immunodeficient mice (such as CB.17 SCID) can allow for long-term adult filarial survival in 
the peritoneum, similar to duration of chronic infections in gerbils, (≥8 months)11–13.
In all models, large variation is evident in the adult parasite success rate from a unit inoculate per animal. 
Variation is comprised of both negative binomial distribution (skewness) and a low occurrence of non-parasitized 
animals (where inoculates have either failed to establish adult infections or where adult infections have only tran-
siently established). Currently, accurate quantitative biomarkers of present adult infections are lacking and thus 
rodents cannot be assessed for infection status or parasitic load prior to enrolment in drug screening. Similarly, 
due to the lack of accurate markers of present adult infection, drug efficacy can only be evaluated at the end-point 
of the experiment, through dissection. To compensate, current screening protocols have long washout durations 
to maximize chances of capturing the ‘true’ efficacy of ‘slow-acting’ macrofilaricides, with concomitant risk of 
reduced survival of remaining adult filariae due to host attrition (independent of drug effect) and/or risk of 
decline in animal welfare. These drawbacks result in the requirement for large experimental group sizes, increased 
costs of maintenance, high demand on complex parasite production and protracted iterative cycles, in order to 
provide decision-making efficacy outputs (e.g. to support pharmaceutical lead-optimisation programmes).
Clinical ultrasonography (USG) has been used in tropical medicine to diagnose and assess therapeutic success 
in numerous diseases14. USG is particularly amenable in the detection of macroparasitic tissue infections due to 
the large size of the pathogens, their distinctive motility and/or the frequent formation of a cystic space in the 
tissues they inhabit e.g. echinococcosis, cysticercosis and filariasis. In LF, Amaral et al first described the random 
thrashing movements of adult W. bancrofti as the filarial dance sign (FDS) in dilated lymphatic vessels during 
scrotal USG15. W. bancrofti USG detection of FDS has been used to diagnose suspected and unsuspected cases 
of scrotal filariasis16,17, and has been an important tool for the evaluation of macrofilaricide and anti-morbidity 
drugs18–22. The reproducible success of USG in detecting FDS in bancroftian filariasis has only been reported in 
the scrotal region in microfilariaemic males, with more inconsistent detection in the lymphatics of other ana-
tomical locations of microfilaraemic female patients23. Similarly, B.malayi, which are smaller than W. bancrofti 
worms (4 cm versus 10 cm) and do not form hydrocoele pathology, have failed to be consistently visualized in 
microfilariaemic patients24.
O. volvulus adult motility within subcutaneous nodules have also been successfully imaged using USG. 
Nodules have been subjected to USG as a method of diagnosis and assessing drug treatment efficacy by determin-
ing changes in nodular structure, as well as imaging the worm motility within cystic spaces inside the nodules25–32.
In a pilot study utilizing rodents infected with L. sigmodontis or B. malayi and pre-determined as positive for 
circulating microfilaraemia, the detection of FDS by USG has been demonstrable with more reliable detection 
in the thoracic cavity versus the lymphatic system33. Here, we have fully assessed the sensitivity, specificity and 
prognostic value of USG to detect FDS of extravascular B. malayi adult filariae contained within the peritoneal 
cavity of SCID mouse and gerbil preclinical drug screening systems. We demonstrate that USG is highly sensitive 
and specific in the detection of FDS using ‘operator-blinded’ studies and can be successfully applied to estimate 
level of adult worm burden and macrofilaricidal efficacy in drug screening experiments.
Materials and Methods
Animals. Male CB.17 Severe Combined ImmunoDeficient (SCID) mice were purchased from Charles River 
UK. Meriones unguiculatus (Mongolian gerbils; jirds) breeding pairs were purchased from Charles River, Europe. 
Breeding and experimental stocks were maintained under specific pathogen-free (SPF) conditions at the bio-
medical services unit (BSU), University of Liverpool, Liverpool, UK. Male SCID mice were 6–10 weeks old and 
weighed 22–26 g at start of experiments. Male gerbils were 4–6 months old and weighed 80–100 g at start of exper-
iments. All experiments were approved by the ethical committees of the University of Liverpool and Liverpool 
School of Tropical Medicine (LSTM) and conducted under Home Office Animals (Scientific Procedures) Act 
1986 (UK) requirements. Animal experiments were undertaken in accordance with NC3Rs ARRIVE guidelines.
Brugia malayi parasite production. The life cycle of Brugia malayi (Bm) was maintained in mosquitoes 
and Mongolian gerbils. For Bm larvae (BmL3) generation, microfilariae (mf) were collected from infected gerbils 
via catheterisation. For this, Mongolian gerbils were anaesthetized with isoflurane and subjected to peritoneal 
washes with RPMI 1640 media (ThermoFisher Scientific) to harvest mf. Mf were then purified using PD10 col-
umn size exclusion chromatography (Amersham), enumerated by microscopy and mixed with human blood to 
a final concentration of 15–20,000 mf/ml. Mf were then fed to female Aedes aegypti mosquitoes through an arti-
ficial membrane feeder (Hemotek). Blood fed mosquitoes were reared for 14 days with daily sugar-water feeding 
to allow development to BmL3 stage. At day 14, BmL3 were collected from infected mosquitoes by crushing and 
concentration using a Baermann’s apparatus and RPMI media.
Brugia malayi Experimental Infections. For BmL3 infection, male Mongolian gerbils, aged 4–6 months, 
were injected via the intraperitoneal route, with with either 50 or 400 highly motile BmL3. Male CB.17 SCID mice 
aged 6–10 weeks, were injected with 100 BmL3. Animals were left for between 12 and 25 weeks post-infection to 
allow infections to proceed to the chronic adult stage.
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Surgical implantation of Adult Brugia malayi parasites. Bm adults were collected from infected 
donor CB.17 SCID mice via peritoneal lavage post-mortem. Parasites were then separated into male and female, 
washed with pre-heated phosphate buffered saline (PBS, Merck) and collected into the following groups: 4x5 
males, 4x5 females, 4x2 males, 4x2 females, 4x1 male, 4x1 female, for implantation (n = 4/group, total n = 28). 
Male SCID mice were then placed under surgical anesthesia using isofluorane and received a subcutaneous injec-
tion of buprenorphine prior to implantation of the above parasite groups into the peritoneal cavity. Implantation 
was achieved by making a small incision into the skin and abdominal cavity in the upper right quadrant and 
inserting parasites into the lower abdominal quadrant using a glass pipette to ensure all parasites were maintained 
in the cavity. The incisions were then re-sutured after implant and animals were re-housed as before and moni-
tored closely. The number of parasites inserted into each mouse was blinded to the investigator and coded by ear 
markings for parasite recovery analysis at the experimental end point.
Preclinical Ultrasonography. To initially optimise the USG technique, a cohort of 5 CB.17 SCID mice were 
surgically implanted with 13 adult Bm parasites and imaged before and after the addition of sterile RPMI media 
to establish a ipFDS signal. Similarly, 8 gerbils infected with varying numbers of BmL3 were imaged before and 
after 1 and 3 ml of RPMI to optimize the imaging protocol. To further assess the accuracy of USG in detecting 
Bm parasites and to determine limits of sensitivity in CB.17 SCID mice, USG was performed blinded one week 
post-surgery. For this, mice and gerbils were anaesthetized with gas isofluorane prior to receiving a 1 ml or 3 ml, 
respectively, intra-peritoneal injection of sterile, pre-heated (37 °C) RPMI media (Merck, UK). The abdominal 
cavity was then gently massaged to distribute the media and dislodge parasites into fluid pockets to enable easier 
detection with USG. The abdominal region was then shaved and imaged by USG (Sonosite® MTurbo® 8.5 Mz 
linear probe, ‘small parts’ preset) for 10–15 minutes with thorough investigation of all quadrants for random 
thrashing movements (ip filarial dance sign; ipFDS) to confirm the presence of parasitic worms. Parasite load 
and location was semi-quantified using a grid scoring method depending on signal strength and number of 
locations in which parasite masses were detected. Animals were scored as ipFDS- (no FDS detection), ipFDS+ 
(a single location with a weak signal), ipFDS++ (a weak signal at >1 locations) or ipFDS+++ (a strong signal 
at ≥1 locations). For the initial validation of ipFDS, the abdomen was firstly imaged using ‘M-mode’ of USG, 
the time motion display, to accurately confirm parasite presence and location due to the recording of very rapid 
movements exhibited by B. malayi FDS, which are not observed with artifacts of respiration, intestinal peristalsis 
or blood flow. For further validation, the ‘Pulse Wave’ modality was applied to depict velocity and flow direction 
both as a waveform. For this, FDS could be confirmed due the random movements and velocity, as opposed to 
erythrocytes, which instead exhibit a constant flow and velocity. For the Colour Flow Doppler, the same param-
eters were examined as a colour map superimposed onto the 2D imaged, whereby flow moving away from the 
probe can by determined in one colour and flow away determined by another. The random FDS of B. malayi 
allows for colours to change more rapidly during video, and more flow observed moving away from the probe.
Drug treatments. Individual mice (unit of replication; n = 5/group) were randomized into treatment groups 
by ear notch ID (001, vehicle, 002 ABZ, 003 FBZ etc.) Mice were dosed with either a known potent macrofilari-
cidal parenteral regimen of flubendazole (FBZ); 10 mg/kg daily s.c. × 5 days, a related BZ drug regimen of alben-
dazole (ABZ) not expected to confer macrofilaricidal activity, at 5 mg/kg twice daily per oral for 7 days or with 
vehicle matching ABZ for 7 days. USG was carried out by an investigator blinded to treatment to detect presence 
or absence of ipFDS as a prognostic marker of macrofilaricidal outcome of the drug screen at +6 weeks.
Endpoint Parasitological assessments. At indicated intervals post-USG imaging, animals were 
humanely culled before adult B. malayi were recovered by extensive peritoneal washes with RPMI medium. 
Parasite numbers were sexed and counted by microscopy. Motility scoring was based on a system whereby 
3 = highly vigorous movements. 2 = slow movements, 1 = twitching, 0 = immotile. Metabolic activity of adult 
B. malayi recovered at necropsy were determined by washing in PBS and individually placing in a solution of 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) reagent (Merck) in PBS (final concen-
tration 0.5 mg/ml). Worms were incubated for 2 hours at 37 °C with 5% CO2. After washing in PBS, adult worms 
were incubated in 100% DMSO for 1 hour at 37 °C with 5% CO2 to dissolve and release the blue formazan prod-
uct. The samples were read at OD 490 nm on a 96-well plate reader (Varioskan, Bio-Rad).
Statistics. Raw or log transformed continuous variables were tested for normal distribution using D’Agostino 
& Pearson omnibus normality tests. Variables that passed normality tests were analyzed by 1 way ANOVA with 
Holm-Sidak’s multiple comparisons tests. Variables significantly different from a normal distribution were ana-
lyzed by Kruskal-Wallis with Dunn’s multiple comparisons tests. Differences in frequency of categorical variables 
were assessed by Chi-Square analysis. Significance was defined at alpha <0.05 and analyzed using GraphPad 
Prism v6.0h. Power analysis was undertaken using sample means and standard deviations of untreated/vehicle 
control gerbil or SCID mouse worm burdens combined from 2–3 independent infection or implantation exper-
iments. With the assumption of proportional variation, sample size was calculated for drug efficacy effect sizes 
of 70% or 90% with a statistical power (1-ß) of >75 < 90% with alpha set at 0.05 using a two-sample T test (Russ 
Lenth PiFace Applet: https://homepage.divms.uiowa.edu/~rlenth/Power/index.html).
Results
Optimisation and characterisation of intra-peritoneal FDS detection. Initial experimentation was 
undertaken to optimise the detection of adult B. malayi FDS within the peritoneum. B. malayi immature adult 
stages were aseptically isolated from SCID mice +6 weeks following infection with 100 L3 ip. Six weeks after 
B. malayi immature adult stages had been surgically implanted into recipient SCID mice (adult filariae = +12 
weeks old), mice were anaesthetised, orientated in a supine position, abdominal hair removed by shaving and 
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abdomen imaged with a Sonosite Mturbo portable USG with 8.5 Mz linear probe. After a maximum of 15 minutes 
imaging, intra-peritoneal (ip) FDS detection was verified in 2/5 animals (Table 1). Mice were then injected with 
1 ml of pre-warmed, sterile RPMI medium ip, and the peritoneum was gently massaged before re-imaging for a 
further 15 minutes. After this intervention, 5/5 animals had detectable ipFDS signal, most frequently observed 
in the upper right or upper left abdominal quadrants in cystic spaces between the abdominal wall and viscera 
using USG M-mode. For further confirmation of FDS, Doppler modalities were applied, whereby the randomised 
movements and velocity of FDS were confirmed through a ‘filled in’ Doppler signal (Fig. 1C), whereas laminar 
flow, exhibited by normal blood flow and respiration patterns display only a thick white edge, with black within. 
The Colour Doppler mode also further validated FDS signal with the blue colour exhibiting the random move-
ment and direction of parasites moving quickly away from and towards the probe, against the red colour which 
signifies normal blood flow, peristalsis and respiration, with these moving only towards the probe in one direc-
tion (Table 1A, Fig. 1A–C and S video 1–3). Similarly, four Mongolian gerbils, that had chronic adult infections 
3 months post-infection with 400 BmL3, received a 1ml injection before imaging, in which no animals scored 
positively for ipFDS. When a further 2 ml (total of 3 ml) media was injected into the peritoneal cavity, 4/4 gerbils 
had detectable ipFDS (Table 1).
Sensitivity and specificity of B. malayi adult parasite loads by USG in operator-blinded studies. 
To assess sensitivity and specificity of USG in the detection of ipFDS, including low level worm burdens, CB.17 
SCID mice were surgically implanted ip with either 10 female and 5 male (n = 16), five female, five male, two 
female, two male, one female or one male B. malayi (all n = 5/group). All B. malayi used were +12–13 weeks old 
sourced from CB.17 SCID donors infected with BmL3. A further five SCID mice were submitted to peritoneal 
surgery and sham implantations. Between one and five weeks post-surgery, animals were imaged by USG for +15 
minutes under anaesthesia following introduction of 1 ml pre-warmed medium and peritoneal massage. Mice 
were imaged in random order, by one of two operators who were blinded to group. The following day post-USG 
imaging, mice were necropsied and numbers of motile male and female adult B. malayi enumerated. Table 2 
details the sensitivity and specificity of USG in detecting adult B. malayi parasites. In Table 2, numbers listed 
in ‘Bm females’ or ‘Bm males’ columns denotes numbers of female or male parasites recovered from individual 
mice and commas separate parasite yields collected from individual mice. In total, at necropsy, 42/46 mice had 
retained one or more motile B. malayi adults post-implantation. Therefore, combined with sham implants, a total 
of 9 mice were confirmed to lack motile B. malayi. The USG operators were able to accurately predict the absence 
of motile B. malayi in the peritoneum of all 9 infection negative mice (no false positives; 100% specificity). The 
operators predicted the presence of motile B. malayi in 36/42 mice (6 false negatives; 85.7% sensitivity). When 
examining the false negative rate according to final worm burden at necropsy, the operators were able to predict 
with 100% sensitivity the presence of >5 adult, motile B. malayi. This sensitivity dropped to 81% when ≤5 adult 
parasites were present in the peritoneum. Comparing the ability of USG to detect low level (≤5) female versus 
male implants, the level of sensitivity was similar (77%, female implants versus 82%, male implants). USG was 
reproducibly able to detect single motile female (7/9) or male (5/5) B. malayi within the peritoneal cavity of mice.
Validation of USG to predict macrofilaricidal activity in preclinical drug screening. We utilised 
a known macrofilaricidal regimen of flubendazole compared with a known non-macrofilaricidal anthelmintic 
regimen of oral albendazole to test whether USG could accurately predict macrofilaricidal activity in live animals 
during drug screening experiments11,34. In both experiments, individual USG operators were blinded to drug 
group and imaging assessments of mice occurred in random order. In experiment A, mice were implanted with 
10 female and 5 male worms and the USG signal was assessed +6 weeks after start of treatment. Necropsies were 
performed immediately after USG to determine parasite worm burden. Metabolic activity and motility assess-
ments of surviving females worms were also undertaken (Table 3). Following de-blinding, ipFDS signal was 
determined in 8/8 vehicle control treated mice, 8/8 ABZ treated mice and 3/9 FBZ treated mice. The frequency of 
ipFDS detection was significantly lower in the FBZ group compared with vehicle or ABZ (P = 0.0009). The USG 
findings were then compared with the parasitological readout of the drug screen, at termination (Table 3). In all 
vehicle and ABZ treated animals, motile adult B. malayi were recovered. The frequency of infection in FBZ treated 
mice was significantly reduced (4/9 mice, P = 0.0039). Evaluating total worm burden, in the vehicle control group, 
ID
ipFDS 
signal
ipFDS signal 
(+1 ml medium ip)
ipFDS signal 
(+3 ml medium ip)
n adult Bm 
recovered
SCID 1 − + nd 6
SCID 2 + + nd 6
SCID 3 + + nd 7
SCID 4 − + nd 7
SCID 5 − + nd 4
Gerbil 1 − − + 2
Gerbil 2 − − + 2
Gerbil 3 − − + 12
Gerbil 4 − − + 67
Table 1. Optimisation of intra-peritoneal FDS detection by ultrasound in anaesthetised mice or gerbils.
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a median of 7 (range 2–12) motile adult B. malayi were recovered per mouse. A similar median recovery was 
evident in the ABZ group, whereas in the FBZ treatment group, median worm burden was significantly reduced 
(P = 0.0003) with the four mice that remained infection positive containing a single female worm. USG signal 
was detected in 3/4 of these mice. Further, motility assessments ex vivo evaluated that the majority of adult female 
B. malayi derived from vehicle and ABZ groups retained vigorous motility whilst the four B. malayi surviving in 
the FBZ group displayed a significantly reduced moribund motile phenotype, indicating a reduction in viability 
(P < 0.00001).
In experiment B, mice were infected with 100 BmL3 and after adult infections had established (+7 
weeks), mice were randomised and treatment commenced. Due to the success of USG to predict profound 
Figure 1. USG identification of rodent intraperitoneal filarial dance sign. Presence of B. malayi worm clusters 
with rapid motility detected in B mode within cystic spaces between viscera and abdominal wall of SCID mice 
(A). Irregular B. malayi motility (filarial dance sign) captured by pulse wave color doppler (B) and pulse wave 
(C). Movements away from the transducer probe in blue, those towards the transducer in red (B).
total adult Bm recovered 
(n) Bm females Bm males Mice n Mice ipFDS+ Mice ipFDS−
12 9,9 3,3 2 2 0
10 9 1 1 1 0
9 7,7 2,2 2 2 0
8 8,6,5 0,2,3 3 3 0
6 4,4,3 2,2,3 3 3 0
5 3 2 1 1 0
4 2 2 1 1 0
2 1 1 1 1 0
5 5 1 1 0
4 4,4 2 2 0
3 3 1 0 1
2 2,2,2,2 4 3 1
1 1,1,1,1,1,1,1,1,1 9 7 2
5 5,5 2 0 2
4 0 0 0 0
3 3,3 2 2 0
2 2,2 2 2 0
1 1,1,1,1,1 5 5 0
0 (including sham) 0 0 9 0 9
total Bm+ 42 36 6
total Bm− 9 0 9
Total 51 36 15
sensitivity 85.7%
sensitivity >5 adult Bm 100%
sensitivity ≤5 adult Bm 80.6%
sensitivity ≤5 female Bm 76.5%
sensitivity ≤5 male Bm 81.8%
specificity 100%
Table 2. Sensitivity and specificity of USG in determining adult motile B. malayi.
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macrofilaricidal activity of FBZ immediately before end-point, in experiment B USG was performed at +2.5 
weeks post-treatment, 3.5 weeks prior to end-point, in order to evaluate the prognostic potential of ipFDS sig-
nal detection in predicting macrofilaricidal drug activity. A different USG operator undertook evaluations in 
experiment B. Following de-blinding of treatment groups, USG undertaken at +2.5 weeks post-dosing detected 
ipFDS signal in 5/5 vehicle and ABZ treated mice. A significantly reduced frequency of ipFDS, in 1/5 FBZ treated 
mice, was detected (P = 0.0042). At the end-point, +6 weeks post-dosing, the frequencies of infection positive 
mice were similar between treatment groups (5/5, 5/5 and 4/5) for vehicle, ABZ and FBZ, respectively. However, 
total adult B. malayi worm burden was significantly reduced in FBZ treated animals compared with vehicle 
(median recovery 1 versus 18, P < 0.0001), whilst worm burdens in the ABZ group remained similar (median 
worm recovery = 19). In the FBZ group, one mouse had four female worms recovered whilst an additional three 
mice contained a single female B. malayi. Motility assessments of recovered adult female worms determined that 
the majority of B. malayi in vehicle and ABZ treatment groups retained vigorous motility whilst the surviving 
FBZ-treated B. malayi displayed significantly reduced and moribund ‘twitching’ motility (P < 0.0001). Metabolic 
activity of sampled female worms was also significantly reduced in both drug groups versus vehicle but to a more 
profound extent in the surviving FBZ-treated B. malayi versus ABZ-treated worms (P < 0.0001).
Application of USG to semi-quantify B. malayi adult parasite loads in vivo. We investigated 
whether the qualitative signal strength of ipFDS determined by USG could be utilised to semi-quantify variation 
in B. malayi adult worm burden that arises following experimental infection with BmL3. Cohorts of CB.17 SCID 
mice (n = 31) or gerbils (n = 14) were assessed after experimental infection and at time-points following adult 
parasite establishment in the peritoneum. Additionally, a group of 4 uninfected gerbils were evaluated (operator 
blinded to infection status). A semi-quantitative scoring system was devised based on number of discreet ipFDS 
signals in anatomical locations of the 4 quadrants of the peritoneum, and also apparent density of ipFDS signal, 
with a low-intermediate signal (+/++) inferring a low density of parasites in either a single or multiple peritoneal 
quadrants and a strong signal (+++) inferring a dense mass of parasites in either a single or multiple quadrants. 
At 40 weeks following infection, 4/31 mice had no detectable ipFDS signal, 12/31 had a low to intermediate signal 
and 15/31 had a strong ipFDS signal. Total B. malayi worm burden was assessed at +41 weeks (Fig. 2A). In 3/4 
mice with no ipFDS signal, no adult B. malayi were found. A single, motile male B. malayi was isolated from the 
other mouse in this group. In mice categorised with a low-intermediate ipFDS signal, median worm burden was 
9.5 (range 3–23) and 50% of the group contained ≥10 adult B. malayi. In mice categorised with a high ipFDS 
signal, median worm burden was 19 (range 8–33) and 87% of the group had a worm burden ≥10. The differ-
ence in worm burden predicted by USG categorisation was significantly different between all sub-groups (1way 
ANOVA F = 10.82, P = 0.0003, Fig. 1A). After a period of between 3–6 months post-infection, the cohort of 
gerbils were subjected to USG and scored as the CB.17 SCID study above (Fig. 2B). Of the gerbils examined, 4/4 
of the sham-infected gerbils had no detectable ipFDS. A further 5 gerbils who had received inoculates of L3 were 
ipFDS negative and were determined to be uninfected at necropsy. Six gerbils were ascribed a low/intermediate 
ipFDS signal and contained a range of 1–2 adult parasites at necropsy. The remaining gerbils scoring a strong 
ipFDS signal contained a median worm burden of 21 (range 12–68). Therefore, in gerbils characterized with a 
high ipFDS, 100% of the sub-group had a worm burden ≥ 10 adult B. malayi, whereas those characterised with an 
intermediate signal, 0% of animals in the group had a worm burden ≥10 adult B. malayi. In both mice and gerbils, 
worm masses were typically visualised underneath the liver or groin area, with number of locations found incor-
porated into the scoring system. The number and location of worm masses could not be accurately correlated at 
Drug 
group+
USG ipFDS+/total 
(weeks post-dosing)
Infection status 
(weeks post-dosing)
median B. malayi 
worm burden 
(range, total n)
Median Female B. 
malayi worm burden 
(range, total n)
Median Male B. 
malayi worm burden 
(range, total n)
Mean Female B. malayi 
metabolic activity  
(SEM, n worms assessed)
Median Female B. 
malayi motility 
score^ (range, total 
n worms assessed)
EXPT A (implant drug screen, USG operator 1)
Vehicle 8/8 (6 weeks) 8/8 (6 weeks) 7 (2–12, 57) 4.5 (1–9, 40) 2 (0–3, 17) 0.40, 39 (0.002) 3 (1–3, 39)
ABZ 8/8 (6 weeks) 8/8 (6 weeks) 7 (2–12, 53) 5 (0–9, 39) 2 (0–3, 14) 0.48, 39 (0.07) 3 (1–3, 39)
FBZ 3/9* (6 weeks) 4/9| (6 weeks) 0† (0–3, 4) 0 (0–3, 4) 0 (0–0) nd 1œ (1–1, 4)
EXPT B (infection drug screen, USG operator 2)
Vehicle 5/5 (2.5 weeks) 5/5 (6 weeks) 18 (9–23, 85) 10 (6–15, 53) 7 (3–8, 31) 0.69, 10 (0.08) 3 (2–3, 10)
ABZ 5/5 (2.5 weeks) 5/5 (6 weeks) 19 (14–21, 93) 14 (11–16, 67) 5 (3–6, 24) 0.28∞, 10 (0.05) 3 (2–3, 10)
FBZ 1/5§ (2.5 weeks) 4/5 (6 weeks) 1# (0–4, 7) 1 (0–4, 7) 0 (0–0, 0) 0.01∞, 7 (0.003) 1∫ (1–2, 7)
Table 3. USG ipFDS detection compared with adult B. malayi parasitological readouts in experimental 
macrofilaricide drug screens. +ABZ = albendazole 5mg/kg twice daily per oral x 7d, FBZ = flubendazole 
10mg/kg once daily sc x 5d. ^Motility score: 3 = vigourously motile, 2 = sluggishly motile, 1 = partial twitching 
motility, 0 = immotile. *Chi-square analysis X2 = 14.04, df,2 P=0.0009. |Chi-square analysis X2 = 11.11, df,2 
P=0.0039. †Kruskal Wallis 1 way ANOVA 16.09, P=0.0003 (Dunn’s tests: vehicle vs FBZ, P < 0.01, ABZ vs FBZ, 
P < 0.01). œKruskal Wallis 1 way ANOVA 18.49, P < 0.0001 (Dunn’s tests: vehicle vs FBZ, P < 0.0001, ABZ 
vs FBZ, P < 0.0001). §Chi-square analysis X2 = 10.91, df,2 P = 0.0042. #Kruskal Wallis 1 way ANOVA 40.13, 
P < 0.0001 (Dunn’s tests: vehicle vs FBZ, P < 0.0001, ABZ vs FBZ, P < 0.0001). ∞1 way ANOVA F = 23.93, 
P < 0.0001 (Holm-Sidak’s tests: vehicle vs ABZ, P < 0.001, vehicle vs FBZ, P < 0.0001, ABZ vs FBZ P < 0.05). 
∫Kruskal Wallis 1 way ANOVA 20.47, P < 0.0001 (Dunn’s tests: vehicle vs FBZ, P < 0.001).
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necropsy due to parasites being purposely dislodged by lavage and thus distributed throughout the peritoneum, 
to allow for easy detection by the dissector.
Evaluation of estimated reductions in animal use for drug screening post-implementation of 
USG assessment. We accumulated data sets of individual adult B. malayi worm burdens derived in multi-
ple preclinical experiments in our laboratory to accurately determine sample variation. Data from experimen-
tal infections of gerbils and SCID mice, as well as recovery of adults post-surgical implantation in gerbils were 
assessed (Table 4). From the sample means and standard deviation in adult burdens we derived minimum group 
sizes to assess with >75 < 90% statistical power a ≥70% or ≥90% reduction in worm burden of an effective 
macrofilaricidal drug. The meta-analysis demonstrated that gerbil infections had increased variation in worm 
burden compared to SCID mice (29.4 ± 33.1, n = 43 versus 15.3 ± 8.7, n = 50) and higher incidence of infec-
tion failures (20% vs 10%). Power calculations determined that nearly 3-fold more animals would be required if 
assessing ≥70% efficacy of a drug candidate in gerbils versus SCID mice (22 versus 8). As prohibitively consuming 
in terms of gerbil use and cost, the alternative strategy of surgically implanting 20 adult B. malayi into gerbil 
recipients from infected donors was adjudged to markedly reduce variation in resultant adult yields at assay end-
point (9.4 ± 4.4, n = 11). Whilst this meant that statistical power of assessing ≥70% efficacy was achieved with a 
group size of seven, when taking into account a 1:1 ratio of donors to recipients, a total gerbil use per drug test of 
n = 14 would be necessary. We then evaluated the potential effect of excluding light infections and/or uninfected 
animals via USG assessment on overall animal use. In gerbils, exclusions of uninfected and low level infections 
Figure 2. Semi-quantification of B. malayi worm burden by USG in SCID mouse and gerbil drug screening 
models. positive and negative ipFDS and ipFDS signal strength, semi-quantified in terms of number of 
anatomical locations and density (+/++ = low-intermediate signal, +++ = strong signal) compared 
with worm burdens of motile adult B. malayi determined at necropsy in 31 parasitised SCID mice (A) or 
18 Mongolian gerbils (B). Horizontal bars represent median values and bars represent interquartile range. 
Percentages in parentheses are numbers of animals in each USG sub-category with a B. malayi worm burden 
≥10 (above shaded area of graph). Significant differences were assessed by 1 way ANOVA with Holm Sidak’s 
multiple comparison’s test (A) or Kruskal Wallis with Dunn’s multiple comparison’s tests (B). Significant 
differences are indicated *P < 0.05, **P < 0.01, ***P < 0.001.
Species/strain Model
worm burden 
mean ± SD 
(sample n, expt n)
n animal/drug test 
(>75% < 90% power)# Proportion 
infections 
excluded (%)
minimum animal 
use/drug test†
≥70% 
efficacy
≥90% 
efficacy
≥70% 
efficacy
≥90% 
efficacy
Pre-USG assessment
Gerbil 400xBmL3 infection 29.4 ± 33.1 (43, 3) 22 14 0% 22 14
Gerbil 20xadultBm implantation 9.4 ± 4.4 (11, 2) 7 5 — 14 10
Mouse CB.17 SCID 100xBmL3 infection 15.3 ± 8.7 (50, 2) 8 6 0% 8 7
ipFDS- excluded
Gerbil 400xBmL3 infection 37.2 ± 33.1 15 9 20% 18 11
Mouse CB.17 SCID 100xBmL3 infection 17.0 ± 7.4 5 4 10% 6 5
ipFDS−/+/++ 
excluded (<10 adults)
Gerbil 400xBmL3 infection 47.4 ± 31.3 9 6 40% 14 9
Mouse CB.17 SCID 100xBmL3 infection 19.5 ± 6.0 4 3 25% 5 4
Table 4. Meta-analysis of B. malayi worm burden variation, statistical power and hypothetical animal use for 
preclinical drug screening pre- and post-implementation of USG imaging assessment. #Statistical power (1-ß, 
α = 0.05) two sample T test (Russ Lenth Piface Applet). †Including donor animals (surgical implantations) or 
animals used but subsequently excluded due to USG criteria.
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would mean that similar total numbers of animals could be used compared with surgical implantations, whilst 
obviating the requirement for invasive surgery, as a beneficial refinement to animal welfare (for ≥70% efficacy, 
14 animals per group). For SCID mice, exclusions of uninfected and low level infections would mean that total 
animal use per drug group tested could be reduced by between 30–40%, depending on required efficacy level 
being evaluated.
Discussion
Intraperitoneal infections of rodents with Brugia spp. are convenient small animal models to test activity of can-
didate filaricidal compounds. However, limitations of the current screening models means large numbers of ani-
mals are required to gauge with accuracy the efficacy level of test compounds. Variation in adult parasite worm 
burden and the occurrence of infection failure in both gerbils and, to a lesser extent, immunodeficient mice, 
hampers the success of screening systems to delineate the true efficacy level of treatments. To compensate for 
variation in worm burden, investigators accommodate large group sizes which is costly and increases overall 
animal use. A second strategy to overcome parasitological variation is the surgical transfer of adult Brugia para-
sites from donor-infected animals prior to drug dosing. Whilst this strategy improves accuracy of drug efficacy 
evaluation, it requires an invasive procedure. A second limitation of current screening systems is that no accurate 
quantitative biomarker of active infection is available. Thus, both initial starting adult biomass and endpoints of 
drug treatment efficacy are difficult to predict. Microfilarial production can be used as a marker of fecund adult 
infection but is not infallible due to occurrence of single sex infections and because mature mf can persist long 
term after the death of adult parasites (half life~100 days). Further, sampling of mf in the peritoneum requires 
invasive catheter washing under anesthesia, which can also coincidently remove adult parasites, particularly male 
Brugia. Ultimately, these drawbacks mean that animals are either maintained for very long durations (up to 8 
months post-drug treatment) with the concomitant risk of welfare issues arising, or multiple groups are used to 
sample different time points after treatment, with yet further increases in overall animal use.
Previously, USG has been used in the field of tropical medicine primarily as a diagnostic tool, and also to 
assess therapeutic outcomes. One example is the use of USG to detect pathology caused by certain parasites, 
such as assessing liver fibrosis and changes in urinary tract structure due to schistosomiasis35. USG has also been 
applied to other diseases, including visceral leishmaniasis and viral haemorrhagic fever, whereby pathological 
changes in different organs can be used to determine disease state and therapeutic efficacies14. In terms of fila-
riasis, USG has been used in the field to detect FDS in hydrocele patients and to determine macrofilaricide and 
anti-morbidity drug activity15,16,18,19,36.
To our knowledge, there has been no literature reported on the use of USG for pre-clinical drug models of 
Brugian filariasis, making this research a novel expansion of the technique to determine efficacy of drug candi-
dates and significantly reduce animal usage in this area.
We tested whether ultrasound detection of adult Brugia ‘filarial dance sign’ could be employed as a specific 
adult filarial biomarker to reduce and refine rodent use for in vivo filarial drug screening. After optimizing the 
technique for ipFDS detection in mice and gerbils, we determined, in multiple operator/operator-blinded studies 
that USG was 100% specific in predicting animals who were infection negative and 86% sensitive in detecting 
active adult B. malayi infection. This increased to 100% sensitivity when >5 adult motile adult parasites were 
present in the peritoneum. The USG technique could be mastered and transferred from one operator to another 
with minimal amount of training and practice and without necessary prior experience of USG. Interestingly, 
sensitivity of ipFDS detection was not significantly different in single sex infections when low numbers of either 
larger, wider female (4–5 cm × 180–230 μM) or smaller, thinner male worms (1–2 cm × 70–80 μM) were evalu-
ated in vivo. Indeed, single male worms were detectable in 100% of animals tested. This highlights a remarkable 
sensitivity of USG to detect adult infection and illustrates sensitivity is more related to the rapidity of filarial 
motility rather than the size of adult worm per se. Reduction in sensitivity of USG detection reduced from 100% 
in animals parasitised with >5 adult worms to 81% in animals containing ≤5 worms. This probably reflects that 
with fewer parasite masses in fewer anatomical locations, a positive ipFDS signal is more likely to be missed over 
the 15 minutes of USG scanning especially if worms are situated in smaller cystic spaces surrounding solid tis-
sues. The results indicate the technique may be able to predictively detect earlier, smaller life-cycle stages such as 
juvenile adult worms or even fourth-stage larvae, which may have use in determining earlier endpoints of drug- 
or immuno-prophylaxis type preclinical studies.
We demonstrated that USG detection of motile adult B. malayi could be successfully applied as an early prog-
nostic measure of effective macrofilaricidal activity. Using flubendazole injection as a reference macrofilaricide, 
as little as 2.5 weeks after dosing, USG could accurately predict if a rapid-acting macrofilaricidal drug regimen 
was significantly efficacious in operator-blinded studies. The predictive power of the USG approach was related 
to both a reduced total adult worm burden but also a severely reduced motility phenotype of surviving worms 
following effective drug treatment. Thus, we conclude that ipFDS signal is an accurate predictor of whether a 
drug candidate is likely to deliver significant macrofilaricidal outcome. Implementing USG to screen animals 
post-treatment would therefore potentially reduce the overall length of washout post-dosing, thus mitigating 
against reduced welfare of protracted animal experiments and the associated risk of underpowered studies requir-
ing reassessment.
When imaging on “B mode”, it was possible to infer a semi-quantitative worm burden based on the apparent 
visual mass of worm movement and also the number of discreet locations where ipFDS was detected. As well as 
identifying sham infections and infection failures with 100% accuracy, this also enabled USG operators to pre-
dict with significant accuracy whether an animal contained a low/moderate or high worm burden, which when 
compared with yield of parasites at necropsy was between 87–100% accurate at delineating animals with ≥10 
adult B. malayi. We evaluated that if implemented prior to randomisation into drug screening experiments, with 
infection negative and light infection animals excluded, this semi-quantitative USG technique would reduce both 
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intra- and inter-group variation and would thus impact on total numbers of animals required for drug screening. 
For gerbil-specific drug screening experiments, a major benefit of USG evaluation would be to negate the neces-
sity of surgically implanting adult parasites from donors to recipients without increasing overall animal use. For 
SCID mouse experiments, animal use could be reduced as much as 40%. Further reductions in animal use over 
and above this would be apparent if experimental designs were altered to reflect the requirement of only a single 
time point for end-point analysis, after implementing longitudinal USG assessments.
In conclusion, USG is a 100% specific and highly sensitive bioimaging technique to detect adult Brugia filarial 
parasites in the peritoneum of infected rodents. The technique can be implemented with minimum training. 
Implementation of USG would be beneficial in terms of refining animal experiments (negating the requirement 
for surgery and invasive sampling) and also has the potential to reduce overall animal use by as much as 40% in 
the context of preclinical anti-filarial drug screening.
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